Christopher S. Brennan, Esq. | Allucent

Christopher S. Brennan, Esq.

Chief Operating Officer & General Counsel

Christopher S. Brennan, Esq.

Chief Operating Officer & General Counsel

Chris Brennan is a seasoned general counsel and business executive who has managed all facets of complex legal, compliance, human resources, regulatory, and government affairs matters, while serving as a valued member of executive management teams for the past 20 years. After serving as an active duty officer in the United States Air Force for over five years during the Gulf War and then earning his law degree, Brennan practiced corporate law for five years at the two prominent and internationally recognized law firms of Cravath, Swaine & Moore LLP and Dechert LLP. Brennan left private practice to launch a venture-capital-backed specialty pharmaceutical company as the second employee. Over the next five years, he served in many administrative and operational capacities, tending to all legal, compliance, human resources, quality, and manufacturing matters as the startup company grew to nearly 100 employees worldwide with a portfolio of over a dozen pharmaceutical products. Brennan went on to serve as a senior member of management as executive vice president, general counsel, and chief compliance officer within the CRO industry at PharmaNet, Bioclinica, and at the world’s largest vitamin, mineral, herbal, and supplement company, Nature’s Bounty. During this time, Brennan worked closely with various well-respected private equity firms, including The Carlyle Group, H.I.G. Capital, JLL Partners, and Water Street Healthcare Partners. After earning a Bachelor of Arts from Fordham University, Brennan went on to earn a Master of Science from Syracuse University and his Juris Doctorate from Fordham University School of Law, where he held the top student position of Editor-in-Chief of the Fordham Law Review.

Partner With the A-Team

Let us know how we can help you bring new therapies to light. Get in touch to get started.

Join the A-Team

Want to help small and mid-sized biotech companies change the therapeutic landscape?

Subscribe to our monthly newsletter